3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Ovarian Neoplasms
13
Neoplasms
8
Breast Neoplasms
7
Neoplasm Metastasis
5
Prostatic Neoplasms
4
Pancreatic Neoplasms
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Urogenital Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumor, Adult
1
Solid Tumor
1
Sarcoma, Ewing
1
Prostatic Diseases
1
Prostate Carcinoma Metastatic to the Bone
1
Ovarian Diseases
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasm, Residual
1
Melanoma
1
Lung Neoplasms
1
Leukemia, Prolymphocytic, T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
HER2-negative Metastatic Breast Cancer
1
Gonadal Disorders
1
Genital Neoplasms, Male
1
Genital Neoplasms, Female
1
Genital Diseases, Male
1
Genital Diseases, Female
1
Interventions
pembrolizumab
49
Paclitaxel
20
Carboplatin
19
Cyclophosphamide
18
Nivolumab
13
Taxes
10
130-nm albumin-bound paclitaxel
10
olaparib
9
Specimen Handling
9
spartalizumab
8
fludarabine
8
Doxorubicin
8
durvalumab
7
Magnetic Resonance Spectroscopy
7
Gemcitabine
7
Biopsy
7
veliparib
6
atezolizumab
6
Fulvestrant
6
Cisplatin
6
Albumin-Bound Paclitaxel
6
liposomal doxorubicin
5
eribulin
5
budigalimab
5
Irinotecan
5
Ipilimumab
5
aldesleukin
4
Radiotherapy
4
Oxaliplatin
4
Leucovorin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Triple Negative Breast Neoplasms
×
niraparib
×
Clear all
NCT03945721
2025-09-29
UNITY
Massachusetts General Hospital
Phase 1
Active not recruiting
21 enrolled